chronic
hcv
infect
treatment
failur
defect
host
immun
respons
highli
demand
improv
therapi
strategi
tcell
may
inhibit
hcv
replic
vitro
ifnc
releas
phosphoantigen
phag
stimul
aim
work
analyz
tcell
function
chronic
hcv
infect
studi
role
ifna
function
capabl
ifnc
product
tcell
analyz
vitro
hcvinfect
patient
healthi
donor
hd
phag
stimul
without
ifna
effect
vivo
phagifna
administr
plasma
ifnc
level
analyz
fasciculari
monkey
quantit
analysi
ifnc
mrna
level
stabil
tcell
also
evalu
chronic
hcv
infect
tcell
show
effectoractiv
phenotyp
significantli
impair
ifnc
product
interestingli
ifna
abl
improv
ifnc
respons
phag
vitro
hd
hcvinfect
patient
vivo
macaca
fasciculari
primat
final
ifna
increas
ifncmrna
transcript
stabil
phagactiv
tcell
altogeth
result
show
function
impair
tcell
chronic
hcv
infect
partial
restor
use
ifna
studi
aim
evalu
antivir
impact
phagifna
combin
may
provid
new
insight
design
possibl
combin
strategi
improv
hcv
infect
treatment
outcom
hepat
c
viru
hcv
infect
evolv
persist
infect
may
progress
fibrosi
cirrhosi
liver
failur
even
hepatocellular
carcinoma
current
standard
therapi
base
combin
pegyl
peg
ifna
ribavirin
rbv
treatment
respons
may
influenc
sever
virusrel
factor
hcv
genotyp
baselin
titer
hcv
rna
sustain
virolog
respons
svr
occur
approxim
patient
infect
hcv
genotyp
approxim
genotyp
new
antivir
strategi
current
develop
hcv
infect
includ
drug
target
key
viral
enzym
rnadepend
rna
polymeras
although
effect
use
new
antivir
seem
associ
select
drugresist
hcv
variant
result
viral
breakthrough
thu
combin
antivir
standard
treatment
ifna
rbv
therefor
necessari
hcv
persist
mainli
due
failur
host
immun
system
effect
definit
clear
infect
gener
protect
cellular
immun
inde
mark
quantit
qualit
defect
hcvspecif
tcell
describ
hcv
patient
correl
innat
immun
cell
impair
dendrit
cell
dc
nk
cell
context
immun
modul
could
repres
promis
strategi
aim
restor
protect
immun
respons
induc
long
last
immun
necessari
obtain
viral
erad
among
innat
immun
cell
tcell
repres
good
target
immunotherapi
infecti
diseas
multifacet
respons
capabl
may
specif
activ
vitro
vivo
use
phosphoantigen
phag
aminobisphosphon
without
mhc
restrict
elicit
dual
antimicrobi
activ
directli
affect
microbi
replic
modul
cell
subset
dc
activ
matur
neutrophil
recruit
activ
immun
respons
polar
tcell
involv
host
respons
mani
chronic
viral
infect
includ
hcv
observ
chronic
infect
hiv
decreas
peripher
tcell
subset
observ
associ
hcv
infect
activ
lymphocyt
found
abl
inhibit
subgenom
hcv
replic
effect
mediat
mainli
ifnc
releas
role
recombin
ifnc
subgenom
hcv
replic
also
describ
moreov
sever
studi
show
combin
recombin
ifnc
ifna
result
strongli
enhanc
antivir
activ
hcv
replicon
model
open
way
new
combin
treatment
approach
thu
ifnc
induc
tcell
stimul
could
enhanc
standard
treatment
effect
work
phenotyp
function
tcell
analyz
chronic
hcv
infect
evalu
possibl
strategi
aim
improv
effector
respons
approach
valid
vivo
nonhuman
primat
model
studi
approv
ethic
committe
nation
institut
infecti
diseas
lspallanzani
enrol
individu
provid
written
inform
consent
experi
monkey
perform
accord
recommend
weatheral
report
previous
approv
region
ethic
committe
plasma
hcvrna
level
assay
abbott
realtimehcv
assay
abbott
laboratori
abbott
park
illinoi
usa
moreov
hcv
genotyp
determin
abbott
realtim
hcv
genotyp
ii
amplif
reagent
kit
peripher
blood
mononuclear
cell
pbmc
isol
lympholyt
cedarlan
canada
select
experi
cd
tcell
purifi
pbmc
immunomagnet
separ
use
anticdconjug
magnet
microbead
miltenyi
biotec
germani
puriti
cell
fraction
experi
measur
flow
cytometri
analysi
data
shown
phenotyp
analysi
tcell
hcv
hd
perform
flow
cytometri
specif
tcell
subset
analyz
use
follow
monoclon
antibodi
fitc
clone
clone
beckman
coulter
immunotech
franc
apc
clone
cychrom
clone
clone
apc
clone
bd
bioscienc
san
jose
ca
usa
briefli
thaw
pbmc
cellsml
incub
mab
cocktail
min
wash
twice
wash
buffer
pb
nan
bsa
fix
paraformaldehyd
pfa
sigma
st
loui
ms
sampl
acquisit
data
analysi
perform
fac
canto
ii
flow
cytomet
becton
dickinson
use
diva
softwar
cytokin
product
tcell
test
use
synthet
phag
innatepharma
franc
abl
specif
activ
tcell
specif
purifi
tcell
hd
n
pbmc
hd
n
hcvpatient
n
stimul
singl
phag
mm
singl
iuml
scheringplough
belgium
phag
plu
combin
stimul
ifnc
product
evalu
hour
elisa
test
thermo
scientif
usa
moreov
select
hcv
hd
frequenc
ifncproduc
tcell
monitor
briefli
pbmc
stimul
h
phag
phagifna
presenc
brefeldin
mgml
serva
germani
block
cytokin
secret
intracellular
stain
perform
stain
cell
minut
fitc
antibodi
wash
cell
fix
pfa
sigma
st
loui
ms
stain
room
temperatur
apclabel
ifnc
specif
antibodi
clone
permeabil
solut
pb
nan
bsa
saponin
wash
pb
nan
bsa
saponin
cell
acquir
flow
cytomet
fac
canto
ii
flow
cytomet
data
analyz
use
diva
softwar
frequenc
ifncproduc
tcell
ifnc
mfi
median
fluoresc
intens
compar
hd
hcvinfect
patient
vivo
drug
administr
cytokin
quantif
anim
system
cynomologu
macaqu
macaca
fasciculari
includ
studi
anim
purchas
noveprim
ferney
se
mahebourg
mauritiu
cdp
ulp
strasbourg
franc
anim
welfar
condit
conform
european
requir
compris
monitor
temperatur
humid
air
chang
light
cycl
experi
previous
approv
region
ethic
committe
dethiqu
en
animal
de
strasbourg
cremea
number
approv
begin
studi
bodi
weight
rang
kg
order
avoid
suffer
anim
anaesthet
ketamin
nd
mgkg
im
procedur
group
anim
inject
sc
mgkg
chdmapp
second
gener
synthet
phag
abl
specif
activ
tcell
innatepharma
franc
solut
borat
buffer
group
anim
inject
subcutan
sc
mgkg
mganim
sc
interferon
pegyl
pegasysh
roch
dose
pegasi
use
clinic
care
hcv
patient
blood
sampl
collect
hour
treatment
sera
store
analysi
ifnc
plasma
level
analyz
elisa
biosourc
rna
purifi
cd
cell
extract
trizol
reagent
invitrogen
usa
one
mg
total
rna
revers
transcrib
taqman
revers
transcript
reagent
kit
appli
biosystem
usa
accord
manufactur
instruct
ifncmrna
level
quantifi
qpcr
perform
use
taqman
pcr
master
mix
appli
biosystem
usa
ht
fast
realtim
pcr
system
machin
use
primer
probe
set
ifncmrna
bactin
describ
result
express
normal
bactin
express
mrna
stabil
evalu
ad
mgml
actinomycin
actd
hour
phag
mm
ifna
iuml
stimul
ifncmrna
level
evalu
qrtpcr
actinomycin
addict
minut
cultur
express
normal
bactin
mrna
stabil
evalu
calcul
halflif
time
ifncmrna
linear
regress
graphpad
prism
statist
signific
determin
graphpad
prism
softwar
graphpad
differ
group
evalu
non
parametr
mannwhitney
test
wilcoxon
test
use
compar
differ
cultur
condit
cell
test
consid
signific
ifncmrna
half
life
evalu
linear
regress
tcell
subset
analyz
hcvinfect
patient
hcv
treatment
compar
healthi
donor
hd
chronic
hcv
patient
slight
signific
decreas
circul
tcell
frequenc
observ
hcv
median
iqr
vs
hd
p
figur
confirm
previou
result
moreov
tcell
differenti
profil
show
signific
increas
effector
cell
hcv
patient
hcv
median
iqr
vs
hd
p
suggest
chronic
hcv
infect
induc
tcell
differenti
toward
effector
function
figur
moreov
express
tcell
slightli
significantli
increas
hcv
patient
compar
hd
hcv
median
iqr
vs
hd
iqr
p
hcv
median
iqr
vs
hd
iqr
p
figur
suggest
hcvinduc
chronic
inflamm
may
increas
basal
activ
cell
well
known
phag
specif
activ
tcell
subset
induc
ifnc
releas
thu
ifnc
product
tcell
hcvinfect
patient
n
hd
n
analyz
stimul
pbmc
hour
tcell
specif
phag
mm
amount
ifnc
releas
supernat
measur
elisa
figur
final
wonder
whether
lower
ifnc
product
observ
chronic
hcv
infect
patient
result
decreas
frequenc
ifncproduc
tcell
reduc
amount
ifnc
produc
cell
aim
quantifi
frequenc
ifncproduc
tcell
intracellular
stain
flow
cytometri
shown
figur
statist
signific
differ
frequenc
phagstimul
tcell
hd
hcv
observ
suggest
hcv
infect
reduc
amount
ifnc
produc
respond
cell
inde
ifnc
mfi
order
evalu
whether
ifna
could
improv
tcell
respons
phag
purifi
tcell
stimul
singl
phag
mm
singl
ifna
iuml
combin
phagifna
hour
end
incub
ifnc
releas
tcell
evalu
elisa
test
figur
shown
figur
moreov
dose
respons
experi
show
ifna
modifi
ec
phag
abl
induc
dose
depend
increas
ifnc
product
data
shown
verifi
ifna
could
also
improv
vivo
tcell
respons
phag
stimul
nonhuman
primat
fasciculari
inject
mgkg
sc
phag
group
n
mgkg
phag
sc
mganim
sc
pegifna
group
n
plasma
ifnc
level
analyz
administr
hour
shown
figur
ifnc
found
treatment
singl
inject
phag
result
increas
plasma
ifnc
level
reach
peak
hour
declin
afterward
interestingli
combin
inject
ifna
phag
abl
strongli
increas
ifnc
releas
c
max
phag
pgml
vs
c
max
phagifna
pgml
show
phagifna
combin
abl
boost
vivo
ifnc
product
figur
notabl
hcvinfect
patient
ifnc
product
tcell
phagifna
stimul
reach
level
found
hd
nevertheless
rel
impact
ifna
improv
individu
tcell
respons
higher
hcvinfect
patient
hd
figur
figur
ifncmrna
persist
studi
block
transcript
actinomycin
hour
stimul
figur
defin
ifncmrna
amount
normal
bactin
mrna
found
hour
stimul
actinomycin
addit
ifncmrna
level
measur
minut
actinomycin
addit
mrna
halflif
calcul
regress
analysi
report
figur
main
aim
work
studi
effect
chronic
hcv
infect
tcell
phenotyp
function
possibl
strategi
aim
improv
effector
activ
chronic
hcv
infect
induc
slight
signific
decreas
frequenc
tcell
increas
liver
tissu
compartment
cell
may
repres
addit
factor
differenti
activ
profil
analysi
tcell
show
increas
circul
effector
activ
cell
data
may
explain
context
chronic
infect
lead
persist
stimul
immun
cell
drive
activ
differenti
patient
correl
found
tcell
dysfunct
clinic
paramet
tcell
play
pivot
role
viral
infect
abil
mediat
broad
antivir
immunomodul
activ
specif
antivir
role
activ
tcell
mainli
mediat
ifnc
releas
demonstr
sever
virus
coronaviru
orthopoxviru
hiv
hcv
work
sever
function
inabl
tcell
produc
ifnc
shown
hcv
patient
independ
viral
load
genotyp
innat
immun
cell
known
show
quantit
qualit
defect
chronic
hcv
infect
dc
nk
cell
could
associ
adapt
immun
respons
dysfunct
andor
exhaust
context
complex
network
differ
signal
act
induc
immun
cell
exhaust
chronic
inflamm
persist
antigen
stimul
andor
direct
viral
effect
chronic
inflamm
persist
antigen
stimul
observ
hiv
infect
may
result
tcell
exhaust
anergi
activationinduc
cell
death
decreas
tcell
respons
downmodul
chain
express
final
although
controversi
possibl
direct
hcvdriven
inhibit
nk
cell
function
bind
report
interestingli
express
cd
tcell
previous
report
studi
aim
defin
cellular
molecular
mechan
involv
tcell
exhaust
chronic
hcv
infect
may
use
evalu
possibl
strategi
restor
activ
main
result
work
demonstr
tcell
function
may
improv
ifna
hd
hcvinfect
patient
result
higher
ifnc
product
first
demonstr
typei
ifn
may
sens
tcell
report
kunzmann
et
al
show
increas
ifna
treatment
confirm
observ
data
shown
show
abil
ifna
increas
tcell
respons
phag
stimul
term
ifnc
product
hd
hcvinfect
patient
particular
signific
impair
tcell
hcvinfect
patient
allow
obtain
complet
restor
ifna
nevertheless
individu
rel
impact
phagifna
costimul
found
much
higher
hcv
patient
due
low
level
respons
phag
thu
possibl
restor
ifnc
product
vivo
combin
standard
ifna
treatment
phag
stimul
may
posit
impact
hcv
inhibit
inde
sever
report
show
ifna
ifnc
may
synergist
inhibit
hcv
replic
vitro
effect
also
report
virus
nevertheless
studi
aim
evalu
antivir
impact
phagifna
combin
ongo
may
valid
new
combin
treatment
strategi
interestingli
phagactiv
tcell
abl
produc
ifnc
also
deploy
mani
differ
respons
pathway
dc
activ
neutrophil
recruitmentactiv
thu
improv
overal
protect
immun
respons
capabl
noteworthi
ifna
effect
phagrespons
found
also
vivo
preclin
trial
nonhuman
primat
induc
increas
ifnc
amount
anim
sera
timecours
studi
vivo
ifna
treatment
tcell
respons
phag
hcvinfect
patient
current
progress
possibl
mechan
mediat
improv
found
ifna
act
increas
ifncmrna
persist
may
result
increas
ifnc
translat
level
similar
observ
report
nk
cell
ifnc
product
stimul
regul
mechan
involv
ifncmrna
stabil
inde
mrna
stabil
consid
one
main
posttranscript
control
mechan
respons
initi
resolut
inflamm
recent
year
new
attent
new
direct
antivir
drug
chronic
hcv
infect
grow
nevertheless
combin
new
treatment
ifnaribavirin
seem
necessari
avoid
emerg
drug
resist
definit
combin
immunomodul
approach
may
contribut
optim
antivir
respons
context
tcell
may
repres
good
target
immunomodul
strategi
abil
easili
activ
vivo
phag
without
hla
restrict
orchestr
complex
network
antivir
immunomodul
activ
show
first
time
ifna
current
use
standard
therapi
abl
improv
tcell
respons
hcv
patient
find
ifnc
act
synergist
ifna
inhibit
hcv
replic
strengthen
ration
test
combin
standard
antivir
immunostimul
therapeut
strategi
aim
futur
vivo
studi
hcvinfect
nonhuman
primat
aim
defin
antivir
capabl
combin
treatment
necessari
assess
safeti
antivir
effect
combin
approach
disclos
cellularmolecular
mechan
involv
thank
dedic
work
memori
fabrizio
poccia
promin
research
field
innat
immun
cd
cell
enthusiast
visionari
innat
cell
base
immunotherapi
infecti
diseas
treatment
die
age
